Author Archives: admin

The Forefront of Treating Hair Loss in Women – Yahoo Lifestyle

Hair loss has long been a chief complaint among women, especially as they age. It affects some 30 million women in the United States alone, according to the Cleveland Clinic, and will significantly impact more than 50 percent of women during their lifetime. The most common cause is female-pattern hair loss (FPHL), also known as androgenetic alopecia. It's a chronic and progressive condition that has a genetic component, but it's also caused by factors related to the actions of hormonesovarian cysts, use of high androgen index birth control pills, pregnancy, and menopause, explains Ken L. Williams Jr., D.O., hair restoration specialist, surgeon, founder of Orange County Hair Restoration in Irvine, California.

Other medical conditions are also to blame for hair loss in women, including thyroid disorders, polycystic ovary syndrome, anemia, and chronic illnessand the use of certain medications, many of which treat these conditions, can also lead to hair loss in women. "Certain types of autoimmune disorders result in a slightly different and often less dramatic hair loss problem known as alopecia areata, an inflammatory condition that causes hair to come out in clumps or patches," says Dr. Williams Jr.

Luckily, we've come a long way in terms of treating hair loss. After all, 100 years ago, remedies involved things like snake oil and bat and chicken dung. "In more recent years, clinically tested topical and oral products, such as Minoxidil and Propecia, have become available, as well as procedures like PRP (platelet rich plasma therapy), and hair transplants," shares Anabel Kingsley, consultant trichologist and brand president for Philip Kingsley. She finds a holistic, personalized, multi-pronged approach to be the most effective way to treat any form of hair loss. "Since there is no 'one size fits all,' you want to optimize all possible factors that can affect the hair growth cycle, such as general health, nutrition, and stress levels, as well as the condition of your hair and scalp," she says.

At Philip Kingsley, she treats clients with their Trichotherapy Regime ($215, saksfifthavenue.com), which is specifically formulated for women with fine hair and reduced volume. "It tackles hair loss from all possible angles via the scalp with intensive daily Scalp Drops($89, neimanmarcus.com),a daily Stimulating Scalp Tonic ($28, net-a-porter.com), a thickening protein spray, and targeted masks to optimize the scalp environment," Kinglsey explains. "It also contains carefully formulated nutritional supplements to help give hair support from within."

Related: The Best Shampoos to Support Thinning Hair and Fight Female Hair Loss

Over-the-counter solutions won't work for every person suffering from hair loss, but there are a number of medical interventions that can stimulate hair growthanti-androgen medication, for example, is recommended for clients experiencing prolonged hair loss. "These medications help prevent further hair loss and encourage some hair regrowth from dormant hair follicles," says Dr. Williams Jr. There is also stem cell therapy, which has expanded greatly over the last few years in treating medical disease. "As opposed to embryonic cells, the initial stigma of using stem cells has decreased since the discovery of using bone marrow, fat cells, umbilical cord cells, and even skin cells to extract stem cells," he explains.

Surgery is also an option, and there are currently two primary surgical techniques or methods used in performing hair transplantation: Follicular Unit Transplantation (FUT) and Follicular Unit Extraction (FUE). "With the FUT technique, a section of scalp is excised with a scalpel, the scalp is brought together with sutures or staples and the hair follicles or hair grafts are inserted into tiny slits placed by the surgeon in the balding recipient area," Dr. Williams Jr. says. "The follicles with a single hair are placed in the front rows to define and create a natural hairline and the more dense, natural occurring follicular units are placed by hand in areas where hair density is needed the most."

FUE, a minimally invasive technique that is being hailed as the most significant improvement in hair surgery, uses a minimal depth scoring punch device to loosen the follicle from the surrounding tissues. "With the FUE procedure, a 0.9 or 1.0 millimeter punch minimal depth scoring excision is used in the skin around the upper part of the follicular unit (hair follicles)," he continues. "The hair follicle is then extracted directly from the scalp and manually placed into tiny slits in the balding area similar to the strip method."

There are still several hair restoration solutions left to be discoveredand experts believe most of us will see the concept of hair cloning come to fruition in their lifetime. "Hair cloning would in effect, disassemble a few hair follicles, multiply these cells in the laboratory and then reintroduce them into the scalp to both rejuvenate miniaturizing hair follicles and induce brand new hairs," Dr. Williams Jr. says. "Other groups have tried this but it has been found that when human follicle cells are cultured, they rapidly lose their functionality."

More here:
The Forefront of Treating Hair Loss in Women - Yahoo Lifestyle

Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s Leronlimab, Bringing the Total to Four Patients – Associated…

VANCOUVER, Washington, March 23, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the third and fourth coronavirus patients were treated with the Companys investigational new drug, leronlimab. The treatment of the third patient occurred on Friday and the fourth coronavirus patient was treated on Saturday. These patients are under the care of the same leading medical center in the New York City area that treated the first and second patients.

The treatment with leronlimab is being administered under an emergency IND recently granted by the U.S. Food and Drug Administration (FDA). The treatment with leronlimab is intended to serve as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19).

Bruce Patterson, M.D., CEO of IncellDx, a diagnostic partner and advisor to CytoDyn, said, IncellDx has developed specific companion diagnostic tests to determine the efficacy and dosing of leronlimab in these severe cases of COVID-19. We believe that leronlimab acts by enhancing the immune response while mitigating the cytokine storm that leads to morbidity and mortality in these patients.

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn said, We are encouraged that the onsite medical team is reporting no safety issues and our team continues to be responsive and supportive in any way we can.

About Coronavirus Disease 2019SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain and it is unclear how easily the virus spreads. COVID-19 is thought to be transmitted person to person through respiratory droplets, commonly resulting from coughing, sneezing and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough and shortness of breath. It is believed that symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure, and that symptoms in patients have ranged from non-existent to severe and fatal. At this time, there are very limited treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additional clinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

Go here to see the original:
Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn's Leronlimab, Bringing the Total to Four Patients - Associated...

Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures | DNA RNA and Cells |…

DetailsCategory: DNA RNA and CellsPublished on Monday, 23 March 2020 16:33Hits: 392

GOSSELIES, Belgium I March 23, 2020 I BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates. These two studies are the pivotal JTA-004 PhaseIII clinical study targeting osteoarthritic knee pain and the PhaseIIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures. The JTA-004 trial has been approved by regulatory authorities in Denmark, and the ALLOB by Belgian regulatory authorities.

Bone Therapeutics now has completed preparations for these trials. It is ready to initiate recruitment in both of these studies as soon as the current situation regarding COVID-19 allows, in those two countries. Bone Therapeutics has taken this decision to support healthcare systems in the respective trial countries, enabling them to concentrate on treating COVID-19 patients whilst necessary.

Bone Therapeutics is now ready to commence clinical trials on both its lead products. Receiving regulatory approvals for both Clinical Trial Applications completes the preparative activity for both studies, said Miguel Forte, CEO, Bone Therapeutics. This means that as soon as the current situation allows, we will be able to start recruiting patients for both clinical studies and continue to develop options for patients suffering knee osteoarthritic pain and difficult tibial fractures, both of which are conditions with a high unmet medical need.

The JTA-004 phase III study is a controlled, randomized, double-blind study. It will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The study expects to enrol 676patients with mild to moderate symptomatic knee osteoarthritis in approximately 20centres in 7European countries and Hong Kong SAR.

The ALLOB Tibial Fracture PhaseIIb study is a randomized, double-blind, controlled study in which the fracture healing potential of ALLOB in patients with difficult fractures in the shinbone (tibia) will be evaluated and compared to standard of care alone after a follow-up period of 6 months. ALLOB will be applied by single percutaneous injection 24-72hours post reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union. The study is expected to enrol approximately 178patients in approximately 40sites in up to 7European countries.

About JTA-004

JTA-004 is companys next generation of intra-articular injectable for the treatment of osteoarthritic pain in the knee. Consisting of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a phaseII study involving 164 patients, JTA-004 showed an improved pain relief at 3 and 6 months compared to Hylan G-F20, the global market leader in osteoarthritis treatment.

About Knee Osteoarthritis

Osteoarthritis (OA), also known as degenerative joint disease, is the most common chronic joint condition in which the protective cartilage in the joints progressively break down resulting in joint pain, swelling, stiffness and limited range of motion. The knee is one of the joints that are mostly affected by osteoarthritis, with an estimated 250M cases worldwide.

The prevalence of knee osteoarthritis (KOA) is expected to increase in the coming years due to increasingly aging and obese population. Currently, there is no cure for KOA and treatments focus on relieving and controlling pain and symptoms, preventing disease progression, minimizing disability, and improving quality of life. Most drugs prescribed to KOA patients are topical or oral analgesics and anti-inflammatory drugs. Ultimately, severe KOA lead to highly invasive surgical interventions such as total knee replacement.

About ALLOB and Bone Therapeutics proprietary, scalable cell therapy manufacturing process

ALLOB is the companys off-the-shelf allogeneic cell therapy platform consisting of human allogeneic bone-forming cells. These cells are derived from cultured bone marrow mesenchymal stem cells (MSC) from healthy adult donors. To address critical factors for the development and commercialization of cell therapy products, Bone Therapeutics has established a proprietary, optimized production process that improves the consistency, scalability, cost effectiveness and ease of use of the ALLOB platform. This optimized production process significantly increases the production yield, generating 100,000 of doses per bone marrow donation. Additionally, the final ALLOB product is cryopreserved, enabling easy shipment and the capability to be stored in a frozen form at the healthcare site. The process does therefore substantially improve product quality, reduce overall production costs, simplify supply chain logistics, increase patient accessibility and facilitate global commercialization compared to an autologous approach. Bone Therapeutics has implemented the optimized production process to produce clinical batches for the upcoming Phase IIb clinical trial in patients with tibial difficult-to-heal fractures.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering PhaseIII development for the treatment of pain in knee osteoarthritis. Positive PhaseIIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal PhaseIII program has been approved by the Danish relevant authorities allowing the start of the study.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the PhaseIIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

SOURCE: Bone Therapeutics

Go here to see the original:
Regulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fractures | DNA RNA and Cells |...

Platelet Rich Plasma and Stem Cell Alopecia Treatment size in terms of volume and value 2019-2022 – Daily Science

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Insights 2018, is a professional and in-depth study on the current state of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry with a focus on the Global market. The report provides key statistics on the market status of the Platelet Rich Plasma and Stem Cell Alopecia Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2018-2025 global Platelet Rich Plasma and Stem Cell Alopecia Treatment market covering all important parameters.

Request Sample Report @https://www.mrrse.com/sample/18928?source=atm

The key points of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market report:

The report provides a basic overview of the Platelet Rich Plasma and Stem Cell Alopecia Treatment industry including its definition, applications and manufacturing technology.

The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2018-2025 market shares for each company.

Through the statistical analysis, the report depicts the global total market of Platelet Rich Plasma and Stem Cell Alopecia Treatment industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018-2025 market development trends of Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

The report makes some important proposals for a new project of Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry before evaluating its feasibility.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/18928?source=atm

There are 3 key segments covered in this report: competitor segment, product type segment, end use/application segment.

For competitor segment, the report includes global key players of Platelet Rich Plasma and Stem Cell Alopecia Treatment are included:

Companies Mentioned in the Report

The report also profiles major players operating in the global platelet rich plasma & stem cell alopecia treatment market based on various attributes, such as company overview, financial overview, pipeline portfolio, product portfolio, business strategies, and recent developments. The players covered in the report include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy.

The global platelet rich plasma & stem cell alopecia treatment market has been segmented as below:

Buy This Report @ https://www.mrrse.com/checkout/18928?source=atm

Reasons to Purchase this Report:

* Estimates 2018-2025 Platelet Rich Plasma and Stem Cell Alopecia Treatment market development trends with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Visit link:
Platelet Rich Plasma and Stem Cell Alopecia Treatment size in terms of volume and value 2019-2022 - Daily Science

Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates – GlobeNewswire

Regulated information

Regulatory authorities approve JTA PhaseIII study in osteoarthritic knee pain and ALLOB PhaseIIb study in difficult fractures

Gosselies, Belgium, 23March 2020, 7am CET BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates. These two studies are the pivotal JTA-004 PhaseIII clinical study targeting osteoarthritic knee pain and the PhaseIIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures. The JTA-004 trial has been approved by regulatory authorities in Denmark, and the ALLOB by Belgian regulatory authorities.

Bone Therapeutics now has completed preparations for these trials. It is ready to initiate recruitment in both of these studies as soon as the current situation regarding COVID-19 allows, in those two countries. Bone Therapeutics has taken this decision to support healthcare systems in the respective trial countries, enabling them to concentrate on treating COVID-19 patients whilst necessary.

Bone Therapeutics is now ready to commence clinical trials on both its lead products. Receiving regulatory approvals for both Clinical Trial Applications completes the preparative activity for both studies, said Miguel Forte, CEO, Bone Therapeutics. This means that as soon as the current situation allows, we will be able to start recruiting patients for both clinical studies and continue to develop options for patients suffering knee osteoarthritic pain and difficult tibial fractures, both of which are conditions with a high unmet medical need.

The JTA-004 phase III study is a controlled, randomized, double-blind study. It will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The study expects to enrol 676patients with mild to moderate symptomatic knee osteoarthritis in approximately 20centres in 7European countries and Hong Kong SAR.

The ALLOB Tibial Fracture PhaseIIb study is a randomized, double-blind, controlled study in which the fracture healing potential of ALLOB in patients with difficult fractures in the shinbone (tibia) will be evaluated and compared to standard of care alone after a follow-up period of 6 months. ALLOB will be applied by single percutaneous injection 24-72hours post reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union. The study is expected to enrol approximately 178patients in approximately 40sites in up to 7European countries.

About JTA-004

JTA-004 is companys next generation of intra-articular injectable for the treatment of osteoarthritic pain in the knee. Consisting of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a phaseII study involving 164 patients, JTA-004 showed an improved pain relief at 3 and 6 months compared to Hylan G-F20, the global market leader in osteoarthritis treatment.

About Knee Osteoarthritis

Osteoarthritis (OA), also known as degenerative joint disease, is the most common chronic joint condition in which the protective cartilage in the joints progressively break down resulting in joint pain, swelling, stiffness and limited range of motion. The knee is one of the joints that are mostly affected by osteoarthritis, with an estimated 250M cases worldwide.

The prevalence of knee osteoarthritis (KOA) is expected to increase in the coming years due to increasingly aging and obese population. Currently, there is no cure for KOA and treatments focus on relieving and controlling pain and symptoms, preventing disease progression, minimizing disability, and improving quality of life. Most drugs prescribed to KOA patients are topical or oral analgesics and anti-inflammatory drugs. Ultimately, severe KOA lead to highly invasive surgical interventions such as total knee replacement.

About ALLOB and Bone Therapeutics proprietary, scalable cell therapy manufacturing process

ALLOB is the companys off-the-shelf allogeneic cell therapy platform consisting of human allogeneic bone-forming cells. These cells are derived from cultured bone marrow mesenchymal stem cells (MSC) from healthy adult donors. To address critical factors for the development and commercialization of cell therapy products, Bone Therapeutics has established a proprietary, optimized production process that improves the consistency, scalability, cost effectiveness and ease of use of the ALLOB platform. This optimized production process significantly increases the production yield, generating 100,000 of doses per bone marrow donation. Additionally, the final ALLOB product is cryopreserved, enabling easy shipment and the capability to be stored in a frozen form at the healthcare site. The process does therefore substantially improve product quality, reduce overall production costs, simplify supply chain logistics, increase patient accessibility and facilitate global commercialization compared to an autologous approach. Bone Therapeutics has implemented the optimized production process to produce clinical batches for the upcoming Phase IIb clinical trial in patients with tibial difficult-to-heal fractures.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering PhaseIII development for the treatment of pain in knee osteoarthritis. Positive PhaseIIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal PhaseIII program has been approved by the Danish relevant authorities allowing the start of the study.

Bone Therapeutics other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the PhaseIIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process.

The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications.

Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at http://www.bonetherapeutics.com.

Contacts

Bone Therapeutics SAMiguel Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief Financial OfficerTel: +32 (0) 71 12 10 00investorrelations@bonetherapeutics.com

International Media Enquiries:Image Box CommunicationsNeil Hunter / Michelle BoxallTel: 44 (0)20 8943 4685neil@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries:NewCap Investor Relations & Financial CommunicationsPierre Laurent, Louis-Victor Delouvrier and Arthur RouillTel: + 33 (0)1 44 71 94 94bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

More:
Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates - GlobeNewswire

Global transcutaneous electrical nerve stimulation market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 – PRNewswire

NEW YORK, March 23, 2020 /PRNewswire/ --

The report on the global transcutaneous electrical nerve stimulation market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Read the full report: https://www.reportlinker.com/p05874196/?utm_source=PRN

The report predicts the global transcutaneous electrical nerve stimulation market to grow with a healthy CAGR over the forecast period from 2019-2025. The study on transcutaneous electrical nerve stimulation market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on transcutaneous electrical nerve stimulation market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global transcutaneous electrical nerve stimulation market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global transcutaneous electrical nerve stimulation market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Growing adoption of transcutaneous electrical nerve stimulation therapy for pain management Rising prevalence of osteoporosis-related joint, bone, or muscle problems is increasing the demand for pain therapy2) Restraints Lack of skilled or trained professionals for the therapy3) Opportunities Growing pool of cancer patients worldwide and increasing use of terms for the treatment of severe cancer-related pain

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global transcutaneous electrical nerve stimulation market is segmented on the basis of surgery procedures, product, and end user.

The Global Transcutaneous Electrical Nerve Stimulation Market by Surgery Procedures Direct Nerve Repair Nerve Grafting Stem Cell Therapy

The Global Transcutaneous Electrical Nerve Stimulation Market by Product Portable Desktop

The Global Transcutaneous Electrical Nerve Stimulation Market by End User Hospital Clinics Others

Company Profiles Medtronic plc Boston Scientific Corporation Abbott Laboratories Nevro Corp NeuroMetrix, Inc. Uroplasty, Inc. Cogentix Medical, Inc. Bioness,Inc. electroCore, Inc.

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the transcutaneous electrical nerve stimulation market.2. Complete coverage of all the segments in the transcutaneous electrical nerve stimulation market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global transcutaneous electrical nerve stimulation market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Read the full report: https://www.reportlinker.com/p05874196/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original:
Global transcutaneous electrical nerve stimulation market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - PRNewswire

Signature gathering halted for $5.5 billion stem cell initiative – Capitol Weekly

News

by DAVID JENSEN posted 03.22.2020

Backers of a $5.5 billion stem cell research initiative in California have suspended their efforts to gather signatures to place it on the November ballot, but are expressing confidence that the proposal will qualify.

In response to questions from the California Stem Cell Report, the campaign said it had run afoul of statewide bans on public gatherings. Voter signatures on petitions to place the initiative on the ballot generally require small gatherings in public places.

Weve suspended all signature gathering for the time being. Sarah Melbostad.

The proposal is intended to refinance the California stem cell agency, which has spent nearly all of the $3 billion it was provided by voters in 2004. It will begin to close its doors next fall unless more funding is provided.

Sarah Melbostad, a spokeswoman forCalifornians for Stem Cell Research, released a statement that said,In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being.

The statement continued,Were proud of our team and proud of the promising and significant number of signatures weve gathered to date demonstrating strong support amongst voters. Were confident that we still have time to qualify and plan to proceed accordingly.

To qualify for the ballot, the valid signatures of 623,212 registered voters are needed. Large numbers of signatures are usually disqualified during the certification process. So tens of thousands of signatures or more beyond the minimum are invariably necessary.

The halt to signature gathering affects other potential ballot measures this fall.

The campaign originally expected to have the signatures gathered by the end of April. The campaign did not respond to a question concerning the number of signatures that it has on hand now.

The California Stem Cell Report understands that petition circulation companies throughout the state are calling in their signatures next week. At that point, reliable figures may be available. The halt to signature gathering affects other potential ballot measures this fall.

The halt to signature gathering affects other potential ballot measures this fall.

Here is the full text of the campaigns statement:In keeping with the Governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being.

As the COVID-19 issue is updating daily, if not hourly, we at the campaign are monitoring the situation very closely and will comply with all statewide, regional and local ordinances.

Were proud of our team and proud of the promising and significant number of signatures weve gathered to date demonstrating strong support amongst voters.

Were confident that we still have time to qualify and plan to proceed accordingly.

When faced with this current situation, were reminded every day how important this initiative is to save and improve the lives of millions of Californians living with chronic diseases and conditions, such as cancer, Alzheimers, heart disease, HIV/AIDS, kidney disease and more.Editors Note: DavidJensenis a retired newsman who has followed the affairs of the $3 billion California stem cell agency since 2005 via his blog, the California Stem Cell Report,where this story first appeared.He has published more than 4,000 items on California stem cell matters in the past 15 years.

Go here to see the original:
Signature gathering halted for $5.5 billion stem cell initiative - Capitol Weekly

Cellphone tracking could help stem the spread of coronavirus. Is privacy the price? – Science Magazine

Phone apps promise to identify the recent contacts of people with COVID-19 more quickly and thoroughly.

By Kelly ServickMar. 22, 2020 , 1:30 PM

IT IS POSSIBLE TO STOP THE EPIDEMIC. Thats the message splashed atopa websitebuilt by a University of Oxford team this week to share new research on the spread of the novel coronavirus. Below that hopeful statement comes a big caveat: To stop the virus spread, health officials need to find and isolate the contacts of infected peoplelots of themand fast. Such contact tracing is a mainstay of infectious disease control. But the Oxford team is one of several now advocating for a new approach: tapping into cellphone location data to track the spread of infection and warn people who may have been exposed.

Several governments in Asia have tried that approach in ways that would run afoul of privacy laws in many other countries. China, for example, has reportedly relied on mass surveillance of phones to classify individuals by their health status and restrict their movements. Now, research teams in Europe and the United States are considering less invasive ways to collect and share data about infections, and some are already developing and testing coronavirus-specific phone apps. Governments, meanwhile, are scrambling to figure out how these potential pandemic-fighting tools could work within data privacy laws and without losing the support of an already wary public.

We dont live in a culture of public trust when it comes to data, says David Leslie, an ethicist at the Alan Turing Institute who studies the governance of data-driven technologies. We live in this age that has been called the age of surveillance capitalism, where our data is abused and exploited. But, he adds, authorities and the public will have to weigh the value of privacy against the possibility that data collection could save millions of lives. These are not normal times.

Tracing the people an infected person recently came near requires widespread testing to diagnose infections in the first place. That testing has been painfully slow to ramp up in the United States and parts of Europeto say nothing of countries elsewhere with fewer resources. Even as more tests become available, state and local health departments may not be able to interview every patient and follow up with every contact. And even the most painstaking interview cant reveal contacts or places that a person just doesnt remember.

The virus that is causing the pandemic, severe acute respiratory syndrome coronavirus 2, poses a particular challenge, says Oxford infectious disease epidemiologist Christophe Fraser. So far, it appears that nearly half of transmissions happen before an infected person has symptoms. That means the virus can spread for days before health authorities even learn of a spreader. No matter how many resources you put into [contact tracing], its never going to keep ahead of the virus, he says. Its always going to be one or two generations ahead.

Fraser and his colleagues have watched U.K. coronavirus cases climb in recent weeks while new cases in China plummeted. Two postdoctoral researchers in his lab described their families in China using a phone app that told them when and where it was safe to go out. We thought, Well, what would we do, if we [built] an app?

Fraser, with Oxford clinician David Bonsall and colleagues, designed a mathematical simulation of how instantaneous digital contact tracing would influence the spread of the virus. To stop the epidemic, health officials must reduce the virusreproductive numberthe average number of people each infected person transmits the virus toto less than one. When the team modeled a scenario in which contacts were notified the instant a person tested positive, it was possible to push the reproductive rate of the virus below that threshold, the team reported in a preprint this week.

It became obvious to us that this was solving a major problem, says Fraser, who adds that his team is advising several European governments, including the United Kingdoms, on digital tracking. The U.K. National Health Service announced on 19 March that it was developing a coronavirus contact tracing app.

At its simplest, digital contact tracing might work like this: Phones log their own locations; when the owner of a phone tests positive for COVID-19, a record of their recent movements is shared with health officials; owners of any other phones that recently came close to that phone get notified of their risk of infection and are advised to self-isolate. But designers of a tracking system will have to work out key details: how to determine the proximity among phones and the health status of users, where that information gets stored, who sees it, and in what format.

Digital contact tracing systems are already running in several countries, but details are scarce and privacy concerns abound. Protests greeted Israeli Prime Minister Benjamin Netanyahus rollout this week of a surveillance program that uses the countrys domestic security agency to track the locations of people potentially infected with the virus. South Korea has released detailed information on infected individualsincluding their recent movementsviewable through multiple private apps that send alerts to users in their vicinity. Theyre essentially texting people, saying, Hey, theres been a 60-year-old woman whos positive for COVID. Click this for more information about her path, says Anne Liu, a global health expert at Columbia University. She warns that the South Korean approach risks unmasking and stigmatizing infected people and the businesses they frequent.

But digital tracking is probably identifying more contacts than you would with traditional methods, Liu says. A contact-tracing app might not have much impact in a city where a high volume of coronavirus cases and extensive community transmission has already shuttered businesses and forced citizens inside, she adds. But it could be powerful in areas, such as in sub-Saharan Africa, that are at an earlier stage of the outbreak, and where isolating potential cases could avert the need to shut down all schools and businesses. If you can package this type of information in a way that protects individual privacy as best you can, it can be something positive, she says.

In countries with strict data privacy laws, one option for collecting data is to ask telecommunications and other tech companies to share anonymous, aggregated information theyve already gathered. Laws in the United States and the European Union are very specific about how app and device users must consent to the use of their dataand how much information companies must disclose about how thosedata will be used, stored, and shared. Working within those constraints, mobile carriers in Germany and Italy have started to sharecellphone location data with health officials in an aggregated, anonymized format. Even though individual users arent identified, the data could reveal general trends about where and when people are congregating and risk spreading infection.

Google and Facebook are both in discussions with the U.S. government about sharing anonymized location data, The Washington Post reported this week. U.S. companies have to deal with a patchwork of state and federal privacy regulations, says Melissa Krasnow, a privacy and data security partner at VLP Law Group. App and devicemakers could face user lawsuits for sharing data in a way that wasnt originally specified in their terms of serviceunless federal or local officials pass legislation that would free them from liability. Now youve got a global pandemic, so you would think that [you] would be able to use this information for the global good, but you cant, Krasnow says. Theres expectations about privacy.

Another option is to start fresh with a coronavirus-specific app that asks users to voluntarily share their location and health data. For example, a basic symptom-checking app could do more than just keeping people who dont need urgent care out of overstretched emergency rooms, says Samuel Scarpino, an epidemiologist at Northeastern University. Health researchers could use also use location data from the app to estimate the size of an outbreak. That could be done, I think, without risking being evil, he says.

For Scarpino, the calculus changes if governments want to track the movements of a specific person who has coronavirus relative to the paths of other people, as China and South Korea have apparently done. That kind of tracking could easily swing towards a privacy violation that isnt justified by the potential public health benefit, he says.

In Germany, which has some of Europes strictest data privacy protections, the government can compel a technology company to share location data on an individual in the interest of national security, says Sebastian Golla, a legal scholar at the Johannes Gutenberg University of Mainz who studies data protection law. But indiscriminate mass tracking of individuals lacks a legal basis, he says. To track people who have or might have coronavirus, Germany and other European countries would need to pass laws specifying how data collection would be restricted to a certain population, for a certain time, and for a certain purpose.

Such laws could be on the way. On 21 March, Frankfurter Allgemeine Zeitung reported that the German health ministry had drafted changes to a law called the Infection Protection Act to allow, among other things, the tracking of people who were in contact with those infected with the coronavirus.

Several emerging projects aim to set up voluntary, privacy-conscious phone tracking systems. This week, a team led by computer scientist Ramesh Raskar at the Massachusetts Institute of Technology released a prototype of an app called Private Kit: Safe Paths. The app stores up to 28 days of a users GPS location data, logged every 5 minutes. If the user tests positive for coronavirus, they can choose to share their recent data with health officials to identify and publicize the places where others may have been at risk of infection.

A future iteration of the app, soon to be released, would compare a users recent locations against the path of an infected person and alert them of potential contact. Users wouldnt learn anything else about the infected personnot their age, their sex, or their geographic path. The team, which includes collaborators from Harvard University and the Mayo Clinic, is in discussions with a dozen cities and nations in all parts of the world, about running pilot trials of the app, Raskar says.

Another app in development in Germany relies partly on location data that Google already stores for its account holders. A person who tests positive could use the appcalled GeoHealthto donate their location history. That data would then be anonymized and stored on a central server, says Gernot Beutel, a stem cell transplant physician at Hannover Medical School who is co-developing the technology. A data analytics platform designed by the software company Ubilabs would compare users movement history to that of infected people, and the app would show them color-coded alerts based on how recently they may have encountered the virus. Though a combination of GPS tracking, wireless network data, and connections between phones via Bluetooth, Beutel says the app should be able to detect when a phone comes within 1 meter of another phone.

Making data submissions voluntary and anonymizing data are good options to maintain civil rights. Its a clean way of legally doing it, Golla says. But such apps will reduce the spread of disease only if a lot of people use them. Liu cautions that because a tracking app cant capture every possible source of infection, it risks creating a false sense of security for users. Just because you dont see a dot on a map where a contact might have been doesnt mean that areas that dont have dots dont have infected people.

Raskars team is working to figure out how many people would need to use the Private Kit app for it to be effective at controlling disease spread. He cant say how many people have downloaded the prototype; the researchers dont collect that information for privacy reasons, he says. Beutel is hopeful that the urgency of the pandemic will inspire much of the population to lay bare their movements and health status. People give their stem cells for patients that need a stem cell transplantation. They give their blood, he says. We hope that people think about the crisis, and are willing to give their data.

With reporting by Catherine Matacic.

Original post:
Cellphone tracking could help stem the spread of coronavirus. Is privacy the price? - Science Magazine

Stem cells may give a respite to COVID-19 infected – The Hindu

While stem cell treatment is not a technique to eradicate or fix coronavirus completely, there is proof to help the idea that infected patients, under the treatment, might be more receptive to survive the disease.

That's because, stem cells oppose viral infection due to the presence of specific qualities known as interferon gamma invigorated qualities (ISGs). These are present in stem cells before their separation process happens. Thus, stem cells can be expected to survive even if they are transferred into a patient with confirmed infection of coronavirus, as per Vipul Jain, CEO, Advancells, a research firm focusing on therapeutic applications of regenerative medicine.

Mr Jain said, Even medical science has determined how influenza virus A/H5N1, with a history of causing intense lung injury, was destroyed by human mesenchymal stromal cells (MSCs) in a mouse. Going back to basics has only expanded the chances of positive outcome.''

Mesenchymal stromal cells (MSCs) are those stem cells which can separate into an assortment of cell types. There are several other properties of MSCs which make them suitable for clinical trials, such as they have ability to reduce inflammation thus regulating the immune system back to healthy and an extraordinary capacity to find the damaged tissues in human body. They can even speed up the recovery of those damaged tissues.

For instance, to achieve desired outcome, specialists have used enormous quantities of MSCs with one patient in Baoshan (Yunnan) who got 3 implantations of 50 million umbilical blood cord derived MSCs, while every Beijing patients got 1 mixture of 1 million cells for every kilogram of weight.

According to Advancells observations, MSCs can be acquired from fat, which implies that everybody can use his/her cells, abolishing any contamination or fatalities. In any case, extending them to the amount required for implantation, takes 2 to 3 weeks which is why it is valuable to cryo-conserve (process of preserving cells prone to damage) an individual reservoir of MSCs, that would permit to get to an early and progressively beneficial treatment.

It may be noted that, some 14 trials have been conducted using stem cells to treat coronavirus patients in China. They recommended stem cells may be the option to fix the extreme organ damage brought about by the virus.

MSCs can lessen the overproduction of immunity cells caused as a response to the virus and lower down the levels of inflammatory substances. Thus, bringing the weak framework and the whole body back to its ordinary state,'' Mr. Jain said.

What can be securely said at this stage following this spearheading study, as per Advancells, is that MSCs demonstrate extraordinary potential to turn into an important part of eradicating something so huge coronavirus itself.

Commenting on India scenario, he further said, Sadly, India is slow in terms of awareness, also it is tough to convince ICMR with innovative ideas. China had used it and all patients who have gone for stem cell therapy were recovered. Israel just announced they would start a stem cell pilot for treating coronavirus.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Go here to read the rest:
Stem cells may give a respite to COVID-19 infected - The Hindu

Global Flow Cytometry Market to Register Impressive Growth, Demand Upheld by Cancer and Stem Cell Research, Says Fact.MR – Bio-IT World

Global flow cytometry market is expected to grow at a staggering CAGR of 11.4% during the forecast period (2020-2025).

DUBLIN 2, IRELAND - Mar 23, 2020 - Increased adoption of flow cytometry is an important development in the field of cell biology. Flow cytometry is a widely accepted method in detecting cancers, cell signaling, tumor characterization, fluorescent protein detection and protein-protein interaction. Moreover, flow cytometry is being increasingly used in stem-cell research where scientists examine cell conversions.

On the back of the aforementioned factors, the global flow cytometry market is set to get leveraged in the future. A staggering CAGR of 11.4% is projected for the forecast period 2020-2025, and the market is anticipated to surpass a valuation of US$ 8,119.6 Mn by the end of the forecast period.

Key Takeaways of Global Flow Cytometry Market Study

Request Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=4633

The global flow cytometry market shows immense potential for future growth. The widespread application of flow cytometry in important life science disciplines such as cancer detection and stem cell research is expected to boost the global flow cytometry markets prospects in the future, concludes a Fact.MR analyst.

Acquisitions to Supplement Market Growth

The global flow cytometry market is dominated by the following players: Becton Dickinson & Company, Merck & Co., Inc., Beckman Coulter, Inc., Thermo Fisher Scientific Inc., SYSMEX CORPORATION, Alere Inc., Miltenyi Biotec, Bio-Techne, Agilent Technologies, Inc. & Bio-Rad Laboratories, Inc. Merck & Co. who constitute the maximum share of the market. The company invests in acquisitions that provide opportunities to supplement organic growth and strengthen product portfolios. Another player, Benton Dickinson and Company, offers Flow Cytometry Instruments, Software, Antibodies and Instruments. These products include BD FACSVerse, BDFACSCelesta and BD LSRFortessa. The company is a leading manufacturer and supplier of flow cytometry devices, antibodies and software.

>>> To Get more insights on flow cytometry market, visit-https://www.factmr.com/report/4633/flow-cytometry-market

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over a thousand reports and 1 million+ data points, the team has scrutinized the healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latestmarket research reportsand industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR11140 Rockville PikeSuite 400Rockville, MD 20852United StatesEmail: sales@factmr.comWeb:https://www.factmr.com/

See original here:
Global Flow Cytometry Market to Register Impressive Growth, Demand Upheld by Cancer and Stem Cell Research, Says Fact.MR - Bio-IT World